- Home
- URGN vs NVAX Comparison
URGN vs NVAX Comparison
Compare URGN & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- NVAX
- Stock Information
- Founded
- URGN 2004
- NVAX 1987
- Country
- URGN United States
- NVAX United States
- Employees
- URGN N/A
- NVAX N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- URGN Health Care
- NVAX Health Care
- Exchange
- URGN Nasdaq
- NVAX Nasdaq
- Market Cap
- URGN 1.1B
- NVAX 1.1B
- IPO Year
- URGN 2017
- NVAX 1995
- Fundamental
- Price
- URGN $27.39
- NVAX $6.69
- Analyst Decision
- URGN Strong Buy
- NVAX Hold
- Analyst Count
- URGN 8
- NVAX 9
- Target Price
- URGN $28.50
- NVAX $10.78
- AVG Volume (30 Days)
- URGN 1.4M
- NVAX 4.4M
- Earning Date
- URGN 11-06-2025
- NVAX 11-06-2025
- Dividend Yield
- URGN N/A
- NVAX N/A
- EPS Growth
- URGN N/A
- NVAX N/A
- EPS
- URGN N/A
- NVAX 2.07
- Revenue
- URGN $96,516,000.00
- NVAX $1,064,651,000.00
- Revenue This Year
- URGN $35.07
- NVAX $59.49
- Revenue Next Year
- URGN $117.83
- NVAX N/A
- P/E Ratio
- URGN N/A
- NVAX $3.23
- Revenue Growth
- URGN 8.00
- NVAX 20.27
- 52 Week Low
- URGN $3.42
- NVAX $5.01
- 52 Week High
- URGN $27.98
- NVAX $11.55
- Technical
- Relative Strength Index (RSI)
- URGN 74.68
- NVAX 37.62
- Support Level
- URGN $24.69
- NVAX $6.20
- Resistance Level
- URGN $26.28
- NVAX $6.80
- Average True Range (ATR)
- URGN 1.87
- NVAX 0.34
- MACD
- URGN 0.32
- NVAX -0.04
- Stochastic Oscillator
- URGN 95.93
- NVAX 29.71
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.